Jiuheng Ruan

Jiuheng Ruan


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 December 2022 in European Journal of Pharmaceutics and Biopharmaceutics
Verified
Journal Article
Closed access
YSYutong Sun
Yutong Sun
CLChao Liu
Chao Liu
SRShoujun Ren
Shoujun Ren
YZYang Zhang
Yang Zhang
JRJiuheng Ruan
Jiuheng Ruan
LFLiang Fang
Liang Fang

10 August 2023 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
LWLiuyang Wang
Liuyang Wang
YPYu Pang
Yu Pang
QZQi Zheng
Qi Zheng
JRJiuheng Ruan
Jiuheng Ruan
LFLiang Fang
Liang Fang
Chao LiuChao Liu
Chao Liu

27 October 2026 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
ZLZefan Liu
Zefan Liu
ZHZhikang Hu
Zhikang Hu
AXAijia Xia
Aijia Xia
QWQiuting Wang
Qiuting Wang
LLLian Li
Lian Li
JRJiuheng Ruan
Jiuheng Ruan
The accumulation of senescent cells in tissues serves as a fundamental driver of aging and age-related pathologies, including chronic inflammation, tissue dysfunction, and organ degeneration. Conventional anti-aging interventions often suffer from limited specificity and off-target toxicity. Currently, developing therapeutic strategies capable of precisely targeting senescent cells is urgent. This review focuses on recent advances in delivery strategies designed to achieve either the selective elimination or functional modulation of senescent cells, with the goal of transitioning from broad-spectrum interventions to precision senotherapy. We systematically discuss the latest developments in senescence-targeting delivery platforms. To realize in vivo senescent-cell clearance, nanocarrier-based systems which are responsive to the senescent microenvironment and immune cell-based approaches are engineered. In parallel, we also reviewed emerging strategies for functional remodeling. Advanced delivery vehicles including lipid nanoparticles, extracellular vesicles, and engineered cell therapies are used to realize metabolic reprogramming and epigenetic modulation. The critical mechanisms of delivery systems in overcoming diverse barriers to improve specificity, bioavailability, and safety are highlighted. In this review, we aim to provide a preliminary framework that could serve as a useful reference for guiding the clinical translation of emerging senotherapies.